Six-month efficacy of Latanoprostene Bunod 0.024% in patients with open-angle glaucoma: Retrospective clinical observational study

PURPOSE: To analyse the 6-month clinical results of latanoprostene bunod (LBN) and to compare the efficacy of LBN in the treatment of open-angle glaucoma (OAG) with other prostaglandin analogues (PGAs), latanoprost and bimatoprost.
METHODS: This retrospective study included 193 patients with OAG. There were 63 patients in the LBN group, 57 in the bimatoprost group, and 73 in the latanoprost group. We examined the intraocular pressure (IOP) changes, retinal nerve fibre layer (RNFL) analyses, and visual field (VF) changes of each group during the 6-month treatment period. Baseline and 6-month data of the LBN group were compared. The 6-month changes of the LBN group were statistically compared with the 6-month changes of the bimatoprost and latanoprost groups.
RESULTS: After six months of LBN use, there was a significant decrease in IOP compared to baseline (p=0.022). No difference was found in terms of other parameters (p>0.05 for each). In other parameters, LBN was similar to bimatoprost and latanoprost (p>0.05 for each).
CONCLUSION: LBN provides a significant decrease in IOP. However, 6-month clinical effects were similar to bimatoprost and latanoprost.

Keywords: Bimatoprost, latanoprost, latanoprostene bunod, primary open-angle glaucoma, pseudoexfoliation glaucoma.